Disease Course, Outcomes, and Complications in Pregnant and Breastfeeding Women with Multiple Sclerosis Treated with Rituximab or Ocrelizumab: A Narrative Review. (PubMed, J Res Pharm Pract) - Sep 14, 2026 - "However, decision-making should be individualized, based on disease severity, timing of exposure, maternal benefit, and neonatal monitoring considerations. Prospective studies and expanded pregnancy registries are needed to better evaluate long-term maternal and infant outcomes."
Journal • Review • CNS Disorders • Infectious Disease • Multiple Sclerosis
|
|
Fereshteh Ashtari; Mahnaz Momenzadeh
|